BackGalmed Pharmaceuticals Overview

Galmed Pharmaceuticals Other Current Liabilities

Latest other current liabilities for GLMD: $360K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$355000.00
28.86% YoYΔ $-144000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Galmed Pharmaceuticals Other Current Liabilities History

Loading

Galmed Pharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Galmed Pharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Galmed Pharmaceuticals (GLMD) FAQ

As of the most recent data (March 2026), GLMD shows a other current liabilities of $360K. That compares with $500K in the prior-year period — down 28.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GLMD's other current liabilities is now $360K (was $500K) — a 28.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Galmed Pharmaceuticals is outperforming or lagging.

Tracking GLMD's other current liabilities over time shows whether Galmed Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $360K That compares with $500K in the prior-year period — down 28.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Galmed Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $360K) with ownership activity and broader fundamentals.

Galmed Pharmaceuticals's other current liabilities is $360K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.